160 related articles for article (PubMed ID: 33225872)
21. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
22. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
[TBL] [Abstract][Full Text] [Related]
23. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
Lea Houston M; Morgan J; Kelso C
Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
[TBL] [Abstract][Full Text] [Related]
24. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
Cairns R; Brown JA; Gunja N; Buckley NA
Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
[TBL] [Abstract][Full Text] [Related]
25. The Toxicology Investigators Consortium Case Registry--the 2011 experience.
Wiegand TJ; Wax PM; Schwartz T; Finkelstein Y; Gorodetsky R; Brent J;
J Med Toxicol; 2012 Dec; 8(4):360-77. PubMed ID: 23055123
[TBL] [Abstract][Full Text] [Related]
26. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
[TBL] [Abstract][Full Text] [Related]
27. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
[TBL] [Abstract][Full Text] [Related]
28. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
Malaca S; Tini A; Umani Ronchi F
Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
[TBL] [Abstract][Full Text] [Related]
29. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
[TBL] [Abstract][Full Text] [Related]
30. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
[TBL] [Abstract][Full Text] [Related]
31. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
[TBL] [Abstract][Full Text] [Related]
32. 'Synthetic cannabis': A dangerous misnomer.
Darke S; Banister S; Farrell M; Duflou J; Lappin J
Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
[TBL] [Abstract][Full Text] [Related]
33. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
[TBL] [Abstract][Full Text] [Related]
34. Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues.
Bonaccorso S; Metastasio A; Ricciardi A; Stewart N; Jamal L; Rujully NU; Theleritis C; Ferracuti S; Ducci G; Schifano F
Brain Sci; 2018 Jul; 8(7):. PubMed ID: 30011896
[TBL] [Abstract][Full Text] [Related]
35. Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons.
Rodrigues TB; Souza MP; de Melo Barbosa L; de Carvalho Ponce J; Júnior LFN; Yonamine M; Costa JL
Forensic Toxicol; 2022 Jan; 40(1):119-124. PubMed ID: 36454481
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and
Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
[TBL] [Abstract][Full Text] [Related]
37. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
Alam RM; Keating JJ
Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
[TBL] [Abstract][Full Text] [Related]
38. Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies.
Obafemi AI; Kleinschmidt K; Goto C; Fout D
J Med Toxicol; 2015 Dec; 11(4):426-9. PubMed ID: 25967137
[TBL] [Abstract][Full Text] [Related]
39. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
[TBL] [Abstract][Full Text] [Related]
40. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
Goncalves R; Labadie M; Chouraqui S; Peyré A; Castaing N; Daveluy A; Molimard M
Clin Toxicol (Phila); 2022 Apr; 60(4):458-463. PubMed ID: 34850659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
